Needham Maintains Buy on Avadel Pharmaceuticals, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raises the price target from $20 to $22.
March 05, 2024 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Avadel Pharmaceuticals and raises the price target from $20 to $22.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100